Testing HP515 for fatty liver disease (NASH/MASH)
Part of Digestive system clinical trials.
This trial tests a new drug called HP515 for people with non-alcoholic fatty liver disease, including NASH or MASH. It aims to see if the drug can help reduce liver fat and improve liver health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- Your liver fat level is at least 10% as measured by a scan.
- You agree to use effective birth control during the study and for 6 months after.
- You do not have cirrhosis or other serious liver conditions.
- You do not have poorly controlled diabetes (HbA1c below 8.0%).
- You have not had major heart or blood vessel problems in the past year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, HSK31679, for people with MASH (a type of fatty liver disease with inflammation and scarring). It aims to see if the drug can help improve liver health.
This trial tests a new oral medication, Chiglitazar, for people who have both type 2 diabetes and a fatty liver condition called MASH (fatty liver with inflammation and scarring). It aims to see if the drug can help improve liver health and diabetes control.
This trial tests two new injections (HRS-4729 and HRS-9531) for people with MASH, a type of fatty liver disease. The study aims to see if these drugs can help reduce liver fat and improve liver health.
This study tests a new investigational drug called IMM-H014 for people with MASH, a type of fatty liver disease. The drug aims to reduce liver fat and improve liver health, and this trial will check its safety and effects.
This trial tests a new medication for people with fatty liver disease. It will see if the drug can reduce liver fat and improve liver health over several doses.
This study tests an experimental drug called SNP-610 for a liver condition called NASH (fatty liver with inflammation). The goal is to see if the drug helps improve liver health compared to a placebo.
Hear when a new NAFLD (Non-alcoholic Fatty Liver Disease) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.